Clinical Trial

Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2026-03-26
Trial Details
NCT Number NCT07398859
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Seasonal Allergic Rhinitis
Enrollment 300 participants
Start Date 2026-03-19
Primary Completion 2026-11 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-27